Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SAMSUNG BIOLOGICS CO.,LTD. |
End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 681000.00 KRW | +0.15% | -4.08% | -17.05% | |
| Sep. 20 | Samsung Biologics Signs $242 Million Drug Manufacturing Deal | MT |
| Sep. 18 | South Korean shares post worst day in a month as chipmakers drop | RE |
| Sales 2023 * | 3,585 B 3 B | Sales 2024 * | 4,138 B 3 B | Capitalization | 48469 B 35 916 M |
|---|---|---|---|---|---|
| Net income 2023 * | 790 B 1 B | Net income 2024 * | 949 B 1 B | EV / Sales 2023 * | 13,3x |
| Net cash position 2023 * | 945 B 1 B | Net cash position 2024 * | 1,445 B 1 B | EV / Sales 2024 * | 11,4x |
| P/E ratio 2023 * | 61,3x | P/E ratio 2024 * | 51,1x | Employees | - |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 24.83% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.15% | ||
| 1 week | -4.08% | ||
| Current month | -7.60% | ||
| 1 month | -9.20% | ||
| 3 months | -8.22% | ||
| 6 months | -14.55% | ||
| Current year | -17.05% |
1 week
673 000.00
706 000.00
1 month
673 000.00763 000.00
Current year
673 000.00833 000.00
1 year
673 000.00920 000.00
3 years
624 000.001 000 000.00
5 years
241 500.001 000 000.00
10 years
125 500.001 000 000.00
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.92% | 11 M$ | -.--% | ||
| 0.43% | 15 M$ | +11.40% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-27 | 681000.00 | +0.15% | 57,048 |
| 23-09-26 | 680000.00 | -2.02% | 79,029 |
| 23-09-25 | 694000.00 | -1.28% | 53,684 |
| 23-09-22 | 703000.00 | -0.99% | 43,888 |
| 23-09-21 | 710000.00 | -1.25% | 60,445 |
End-of-day quote Korea Stock Exchange, September 26, 2023
More quotes
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2023-10-23
- CPHI Worldwide
Trading Rating :
Investor Rating :
ESG Refinitiv :
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
681000.00KRW
Average target price
1044901.48KRW
Spread / Average Target
+53.44%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| -17.05% | 35 888 M $ | |
| -87.60% | 74 M $ | |
| +78.04% | 2 609 M $ | |
| -44.68% | 57 M $ | |
| -51.45% | 145 M $ | |
| -58.44% | 251 M $ | |
| +80.97% | 955 M $ | |
| 0.00% | 1 307 M $ | |
| -18.18% | 1 016 M $ | |
| -23.73% | 23 947 M $ |
